SR1664, a novel compound developed by the Scripps Institute in the United States and other institutions, is a PPARγ ligand that activates PPARγ to suppress PPARγ Ser273 phosphorylation, leading to enhanced insulin sensitivity, thereby playing a role in treating type 2 diabetes [4]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.